Patent · US Active

Method of testing a gene therapy vector

US11834722B2 · kind B2 · utility

0Cited by
0References
19Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJul 9, 2018
Grant dateDec 5, 2023
Priority date
Expiry dateSep 15, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

A method of determining the safety and/or efficacy of a gene therapy vector prior to carrying out gene therapy on an individual includes infecting a culture of induced pluripotent stem cells obtained from the individual with a gene therapy vector. Ideally the cells are allowed to differentiate, and the infection is carried out at the start of culture and at least once during differentiation and/or after differentiation. Nucleic acids are extracted from the infected cells, and then analysed to measure and/or determine adverse effects of integration of nucleic acid from the vector and/or efficiency of expression of nucleic acid from the vector.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.